Suven Pharmaceuticals Q2 Results FY27: Profit Falls 82.09%, Revenue Rs 416.69 Cr, PAT Rs 13.27 Cr
- November 7, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Suven Pharmaceuticals Q2 Results FY27 were declared on 6 November 2026 on a Standalone basis. The quarterly results show revenue of Rs 416.69 Cr, down 25% from Rs 555.57 Cr in the same quarter last year. Net profit stood at Rs 13.27 Cr against Rs 74.08 Cr a year earlier, so YoY growth in net profit was negative 82.09%.
Suven Pharmaceuticals Ltd (COHANCE) Q2 Results FY27 announced on 6 November 2026, covering the company’s financial performance for the July to September quarter. Revenue was Rs 416.69 Cr and net profit (PAT) was Rs 13.27 Cr. The results date and the Standalone basis are stated in every figure below, and Suven Pharmaceuticals Q2 Results FY27 are read against the same quarter of last year.
This results analysis of Suven Pharmaceuticals Q2 Results covers the financial highlights, business factors, outlook and risks behind the quarter. Univest tracks these declared figures for readers who compare filings, so the Financial Highlights section below places revenue and net profit side by side with the year earlier numbers.
Click Here – Get Free Investment Predictions
Suven Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 416.69 Cr | Rs 555.57 Cr | -25% YoY |
| Net Profit (PAT) | Rs 13.27 Cr | Rs 74.08 Cr | -82.09% YoY |
Source: company filing for Suven Pharmaceuticals Q2 Results FY27, 6 November 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Suven Pharmaceuticals Q2 Results: What Stands Out
- Revenue fell 25% YoY: Revenue came in at Rs 416.69 Cr this quarter, against Rs 555.57 Cr in the same quarter of the previous year.
- Net profit fell 82.09% YoY: PAT was Rs 13.27 Cr compared with Rs 74.08 Cr a year earlier, a sharp negative reading on YoY growth.
- Profit moved by more than revenue: Suven Pharmaceuticals Q2 Results FY27 show net profit down 82.09% while revenue is down 25%, a gap that follows directly from the supplied figures.
- Net profit margin narrowed: It stood at 3.2% this quarter against 13.3% in the comparison quarter, based on the declared revenue and net profit.
- Balance sheet marker: The company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26, and return on equity was 4.02% in FY26.
- Next step: The performance analysis below shows how revenue and net profit connect across the quarter.
Suven Pharmaceuticals Q2 Results FY27: Performance Analysis
Suven Pharmaceuticals Q2 Results FY27 show Standalone revenue of Rs 416.69 Cr for July to September 2026, against Rs 555.57 Cr a year earlier, a fall of 25% YoY. Net profit was Rs 13.27 Cr against Rs 74.08 Cr, down 82.09% YoY. Both lines are lower than the same quarter of last year.
The gap between the two moves is visible in the arithmetic. Revenue fell by Rs 138.88 Cr, while net profit fell by Rs 60.81 Cr, so the decline in profit is larger in percentage terms. This results analysis also shows net profit at 3.2% of revenue now against 13.3% in the comparison quarter.
Investors following YoY growth will watch later quarterly results, because one quarter does not set the full year. The declared numbers confirm what changed in revenue and net profit, but they do not establish the specific cause. Suven Pharmaceuticals Q2 Results on a Standalone basis therefore lead into the business factors, which is where the results analysis turns next.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Almost Debt Free – The results analysis points to a balance sheet marker among the business factors: the company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26. Suven Pharmaceuticals Q2 Results FY27 therefore sit alongside a very low level of debt against assets.
Debt-to-Assets Ratio of 0.04 – A ratio of 0.04 in FY26 means debt was a very small share of total assets. This is a disclosed factor for the quarterly results, stated as a fact about the balance sheet rather than as the cause of the revenue or net profit change.
Reading the Factor Against the Numbers – The disclosed factor does not explain why revenue fell 25% YoY or why net profit fell 82.09% YoY, so it is context for the quarter and not a stated driver. The outlook section covers what this means for FY27.
FY27 Outlook After Suven Pharmaceuticals Q2 Results
This results analysis stays with the declared figures and does not rely on any management guidance. FY27 full-year results will depend on the quarters that follow and on disclosed conditions in the company’s business. Suven Pharmaceuticals Q2 Results FY27 set the second-quarter base for that comparison.
For net profit, the reference point is Rs 13.27 Cr for July to September 2026 against Rs 74.08 Cr a year earlier. Later FY27 filings will show whether net profit stays near this level or moves again, and the risks below set out what to watch.
Key Risks to Watch After Suven Pharmaceuticals Q2 Results FY27
Revenue Declined 25% YoY
Revenue declined 25.0% year on year to Rs 416.69 Cr in the latest quarter. A further fall in revenue would affect every line below it, so the next filing is the clearest place to check this risk.
Net Profit Fell 82.09% YoY
Net profit fell 82.1% year on year to Rs 13.27 Cr. After Suven Pharmaceuticals Q2 Results FY27, readers can track whether YoY growth in net profit stays negative in later quarters.
Net Profit Margin and Return on Equity
Net profit margin narrowed to 3.2% from 13.3% in the comparison quarter, and return on equity was low at 4.02% in FY26. Both measures are worth tracking in later filings from the company.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Suven Pharmaceuticals Q2 Results FY27 show Standalone revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, both lower than a year ago. These quarterly results record a 25% fall in revenue and an 82.09% fall in net profit. Investors tracking Suven Pharmaceuticals Q2 Results can compare later standalone results on the Univest Screener, and should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Suven Pharmaceuticals Q2 Results FY27
What are Suven Pharmaceuticals Q2 Results FY27?
Ans. Suven Pharmaceuticals Q2 Results FY27 cover July to September 2026 on a Standalone basis, with revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, as the Quick Answer sets out.
What is the results date for Suven Pharmaceuticals Q2 Results FY27?
Ans. The results date for Suven Pharmaceuticals Q2 Results FY27 is 6 November 2026, when the company declared its quarterly results, which means the figures in the Financial Highlights table are tied to that filing.
What revenue was reported in Suven Pharmaceuticals Q2 Results FY27?
Ans. Suven Pharmaceuticals Q2 Results FY27 report revenue of Rs 416.69 Cr for July to September 2026, compared with Rs 555.57 Cr a year earlier, as shown in the Financial Highlights table.
What net profit was reported in Suven Pharmaceuticals Q2 Results FY27?
Ans. Net profit in Suven Pharmaceuticals Q2 Results FY27 was Rs 13.27 Cr, compared with Rs 74.08 Cr in the same quarter last year, so the Financial Highlights table shows a clear fall.
How much YoY growth did revenue show in Suven Pharmaceuticals Q2 Results FY27?
Ans. Revenue in Suven Pharmaceuticals Q2 Results FY27 showed YoY growth of negative 25%, a fall from Rs 555.57 Cr to Rs 416.69 Cr, which is explained in the Performance Analysis section.
Did net profit rise or fall in Suven Pharmaceuticals Q2 Results?
Ans. Suven Pharmaceuticals Q2 Results show net profit falling 82.09% YoY, from Rs 74.08 Cr to Rs 13.27 Cr, while the Key Takeaways section places this fall next to the 25% revenue decline.
What was the net profit margin in Suven Pharmaceuticals Q2 Results FY27?
Ans. Suven Pharmaceuticals Q2 Results FY27 put net profit margin at 3.2%, against 13.3% in the comparison quarter, which means profit took a smaller share of revenue, as the Key Risks section notes.
Are Suven Pharmaceuticals Q2 Results consolidated results or standalone results?
Ans. Suven Pharmaceuticals Q2 Results are standalone results, with revenue of Rs 416.69 Cr and net profit of Rs 13.27 Cr, and the Standalone basis applies to every figure in the Financial Highlights table.
What business factors shaped Suven Pharmaceuticals Q2 Results FY27?
Ans. The disclosed factor for Suven Pharmaceuticals Q2 Results FY27 is that the company is almost debt free, with a debt-to-assets ratio of 0.04 in FY26, as covered in the Key Business Factors section.
What are the key risks after Suven Pharmaceuticals Q2 Results FY27?
Ans. Key risks after Suven Pharmaceuticals Q2 Results FY27 are the 25% revenue fall, the 82.09% net profit fall and the narrower 3.2% net profit margin, which the Key Risks section covers in detail.
What is the outlook after Suven Pharmaceuticals Q2 Results?
Ans. After Suven Pharmaceuticals Q2 Results, FY27 full-year results will depend on later quarters and disclosed conditions, so the Outlook section treats the second quarter as the base for comparison.
Where can I find the complete Suven Pharmaceuticals Q2 Results FY27 data?
Ans. The complete Suven Pharmaceuticals Q2 Results FY27 data sits in the Financial Highlights table above, while the Univest Screener lets readers compare these quarterly results with later filings and other companies.
